What Is an FDA Type B Meeting and How Does It Work?

An FDA Type B meeting is a formal meeting between a drug or biologic sponsor and the FDA, tied to a major development milestone such as a pre-IND discussion, an end-of-phase meeting, a pre-NDA or pre-BLA review, or a post-action meeting after a complete response letter. The FDA must schedule it within 60 calendar days of receiving the request and will grant it “except in the most unusual circumstances.”¹ The mechanics matter, because the scheduling clock, the briefing package deadline, and the questions you submit all shape whether the meeting produces useful FDA feedback or wastes months.

Which Milestones Qualify

Type B meetings are pinned to specific turning points in a development program. Each addresses a different regulatory question, and FDA feedback at these stages often shapes years of subsequent work.

A pre-IND meeting is the earliest opportunity to discuss whether animal safety data and early manufacturing information are sufficient to support first-in-human testing. Sponsors typically bring their proposed first-in-human study design and ask whether the nonclinical package is adequate. Alignment here avoids submitting an IND that the FDA immediately places on clinical hold.

End-of-Phase 1 meetings apply to drugs being developed for serious or life-threatening conditions under 21 CFR Part 312 Subpart E.² These fall under the Type B End-of-Phase subcategory with a 70-day scheduling window. The discussion covers early safety signals, dose selection, and whether the data supports moving into larger efficacy studies.

End-of-Phase 2 meetings are the most consequential for most sponsors. The FDA reviews Phase 2 efficacy and safety results and gives detailed input on Phase 3 trial design: primary endpoints, patient population, statistical analysis plans, study duration, and enrollment targets. Reaching consensus before Phase 3 enrollment starts dramatically reduces the risk of an unapprovable application later.

Pre-NDA and pre-BLA meetings happen just before submission of a marketing application. The focus shifts from science to logistics: is the application complete, are the datasets organized correctly, and are there outstanding manufacturing or labeling questions. These meetings are less about winning FDA blessing on the data and more about avoiding a refuse-to-file decision.

Post-action meetings occur after the FDA issues a complete response letter, the formal notice that the application cannot be approved as submitted. The meeting lets the sponsor ask clarifying questions about the letter’s findings and explore what a successful resubmission would require.

Meetings about Risk Evaluation and Mitigation Strategies that arise outside the review of a marketing application also qualify as Type B.³

How Type B Fits Among the FDA Meeting Types

If you are unsure whether your topic actually belongs in a Type B, the other categories set the boundaries. Type A meetings, scheduled within 30 days, are reserved for programs that have stalled and cannot move without FDA input, such as a clinical hold or a critical safety issue. Type C meetings, scheduled within 75 days, are the catch-all for formal meetings that do not qualify as A or B, including chemistry and manufacturing questions or general development strategy that does not rise to milestone level.¹

Mislabeling matters. Requesting a Type B for a topic that belongs in Type C can trigger a denial and force you to start the process over.

What Goes in the Meeting Request

The FDA distinguishes between elements a request “should” contain and elements it “must” contain. In practice, skipping any of them risks a denial or an unproductive meeting.³

Recommended elements include any assigned application number; product name, chemical name, and structure; the proposed regulatory pathway (for example, 505(b)(1) or 505(b)(2)); the proposed indication; the meeting type you are requesting; suggested dates consistent with the scheduling window along with dates your team is unavailable; and the questions you want to put to the FDA, grouped by discipline with brief context for each.

Mandatory elements include the proposed meeting format (face-to-face, teleconference or videoconference, or written response only); the date you commit to submitting the briefing package; a statement of purpose covering agenda issues, completed and planned studies, and where the meeting fits in the timeline; specific objectives; a proposed agenda with time allotments; an attendee list with names and titles for your team, consultants, and interpreters; and any requested FDA attendees beyond the usual review team, with a justification and a note on whether you would accept a later meeting date to accommodate them.

The questions deserve particular care. Vague questions produce vague answers. The most useful phrasing lets the FDA state a clear position, such as “Does FDA agree that Study X is adequate to support the primary endpoint?”, followed by a short rationale that explains the regulatory challenge behind the question.

The Timeline From Request to Meeting

Submitting the meeting request through the FDA’s electronic gateway starts a series of deadlines drawn from the PDUFA VII performance goals. The FDA is expected to meet these for at least 90 percent of meetings.¹

Day 0. FDA receives the meeting request.
By Day 21. FDA grants or denies the meeting. A grant includes the scheduled date and format.
30 days before the meeting. The sponsor submits the briefing package. A grossly inadequate or missing package can lead the FDA to cancel the meeting.
By Day 60. The meeting takes place, or the FDA issues a written response.

For Type B End-of-Phase meetings, the scheduling window is 70 days rather than 60. The 21-day response deadline and 30-day briefing package deadline stay the same.¹

The arithmetic is tight. If the FDA schedules the meeting on Day 60, the briefing package is due on Day 30, just nine days after you learn the date. Most experienced sponsors begin preparing the package before the meeting is even granted, because waiting for confirmation leaves almost no time to assemble a thorough document.

The Briefing Package

The briefing package is what the FDA uses to prepare its responses. A weak package produces poorly informed feedback or no meeting at all. It should include a summary of the drug’s development history, all relevant clinical and nonclinical data, the statistical analysis plan, and details about manufacturing controls.³

The finalized list of questions goes in the package as well, each paired with a position statement: your proposed answer and the data supporting it. A focused package with clear summaries and a logical structure will generate more useful feedback than a much longer submission that buries the key questions in clinical study reports. Lead with the most important questions, present data in tables where possible, and make your position explicit rather than forcing reviewers to guess what you are asking for.

Meeting Formats and Preliminary Responses

Type B meetings run in one of three formats: face-to-face (which now includes virtual meetings with audio and video), teleconference, or written response only. The sponsor proposes a preferred format in the request; the FDA makes the final choice.³

Before the meeting itself, the FDA sends preliminary written responses to the sponsor’s questions. Reviewing these in advance is critical. If the FDA has already answered several questions clearly in writing, you can skip those during the live discussion and spend limited meeting time on areas where the agency’s position is unclear or where you disagree. When the preliminary responses are comprehensive enough, some sponsors cancel the meeting and rely on the written feedback, though doing so forfeits the chance to push back in real time.

Meeting Minutes and Why They Matter

The FDA issues official minutes within 30 calendar days of the meeting.¹ The minutes are the formal record of every agreement reached and every position the FDA communicated. Sponsors routinely reference them in later submissions to demonstrate that a particular trial design or data package was discussed with and accepted by the agency.

Read the minutes carefully. If the record says the FDA agreed to a particular primary endpoint and the sponsor does not object, that agreement stands. If the minutes misstate the agency’s position and the sponsor stays silent, the misstatement becomes the record. Requesting a clarification or correction promptly protects the regulatory path.

If the FDA Denies the Meeting or You Disagree With Its Position

Because Type B and Type B End-of-Phase meetings are granted except in “the most unusual circumstances,” outright denials are rare.¹ When they happen, the most common reasons are that the meeting is premature, meaning the sponsor lacks enough data to make the discussion productive, or that the request was mislabeled and belongs in a different category.

For substantive disagreements with an FDA scientific or regulatory position, whether stated in a meeting, in preliminary responses, or in meeting minutes, sponsors have a formal appeals process. The first step is resolving the dispute at the division level with the review team that issued the decision. If that fails, the sponsor can file a Formal Dispute Resolution Request with the Office Director overseeing the division.⁴

An effective request lays out the issue, summarizes prior discussions at the division level, and states the outcome the sponsor seeks. The sponsor can ask for a meeting as part of the appeal, though the Office Director decides whether to grant one. If new data or analyses appear for the first time in the appeal, the Office Director may send them back to the division for initial review rather than ruling directly. Put new evidence in front of the division first and escalate only after that discussion has run its course.

User Fees

Type B meetings do not carry a separate meeting fee. The broader drug development process that triggers them does come with substantial obligations under the Prescription Drug User Fee Amendments and, for biosimilars, the Biosimilar User Fee Amendments, which fund the review infrastructure that supports these meetings.⁵⁶ Biosimilar sponsors follow a parallel meeting structure governed by BsUFA-specific guidance.⁷

1
U.S. Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures
2
eCFR. 21 CFR Part 312 Subpart E – Drugs Intended to Treat Life-Threatening and Severely-Debilitating Illnesses
3
U.S. Food and Drug Administration. Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products
4
U.S. Food and Drug Administration. Formal Dispute Resolution – Sponsor Appeals Above the Division Level
5
U.S. Food and Drug Administration. Prescription Drug User Fee Amendments
6
U.S. Food and Drug Administration. Biosimilar User Fee Amendments
7
U.S. Food and Drug Administration. Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry